The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

Coya Therapeutics, Inc. (COYA) closed the last trading session at $6.51, gaining 8.5% over the past four weeks, but there ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Lupin Digital Health has launched a Post-Procedure Home-Based Care Guide, developed alongside the American College of ...

Lupin Digital Health (LDH), India's leading evidence-based Digital Therapeutics (DTx) platform, today announced the launch of ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

We are thrilled to welcome Michael to Avalo’s Board of Directors during this pivotal time in our Company’s growth,” said Dr. Garry Neil, CEO of Avalo Therapeutics. “Michael’s extensive experience in ...

Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...

The UK Health Security Agency has developed a toolkit to guide research and preparedness efforts in biosecurity.

The list of 24 pathogen families is the first to consider global health threats, as well as threats specific to the UK ...

The firm's Heart-2 study of VERVE-102, which is designed to inactivate the PCSK9 gene, is already underway in Canada and the UK.